GSTM1 & GSTT1 Null Genotype: Complete Gene Deletion Affecting Half the Population
These aren't reduced-activity variants. GSTM1 and GSTT1 null genotypes mean the gene was deleted entirely — zero enzyme produced. Approximately 50% of European and Asian populations carry GSTM1 null; roughly 20% carry GSTT1 null. Double-null occurs in ~10–15%.
Why Null Is Different From Other Variants
Most genetic variants discussed in precision medicine are SNPs — single nucleotide changes that reduce enzyme activity by 20–60%. GSTM1 and GSTT1 null genotypes are different in kind, not degree.
These are copy number variants (CNVs) — the entire gene is absent from one or both chromosomes. There's no enzyme to up-regulate, no cofactor to add. The detoxification capacity for the specific substrates these enzymes handle is simply gone.
Crucially, there are other GST isoforms (GSTA, GSTM2–5, GSTP1) that remain functional in null carriers. The compensatory strategy is to maximally upregulate remaining isoforms via NRF2 activation — primarily with sulforaphane — while increasing the raw glutathione pool to compensate for reduced conjugation efficiency.
Genotype Profiles
Full baseline detox capacity for GSTM1 and GSTT1 substrates. You still benefit from sulforaphane and glutathione support — but the urgency is lower. Focus on other rate-limiting variants in your genome.
The most common high-risk configuration. Zero GSTM1 enzyme activity. GSTM1 handles the most clinically significant carcinogen substrates (tobacco smoke, benzene, PAHs). Risk elevation is particularly well-documented for bladder cancer (OR ~1.5–2.0) and lung cancer in smokers (OR ~2.0–3.5).
Priority intervention: Sulforaphane 40–60mg/day + liposomal glutathione 500mg/day.
Less common than GSTM1 null but particularly relevant for halogenated compound exposure (chlorinated water, solvents, certain pesticides). GSTT1 null is more strongly linked to meningioma risk and myelodysplastic syndromes. Sulforaphane is still first-line, but selenium support becomes more critical (GSTT1 handles some of the same substrates as GPx).
Both mu and theta class GST activity is zero. This is the highest-risk genotype for multiple cancer types when combined with relevant environmental exposure. Meta-analyses show 2–4× elevated risk for bladder and lung cancer in smokers with double-null status.
Full support stack required: Maximum sulforaphane + liposomal GSH + NAC + glycine + selenium + milk thistle. This is not optional supplementation.
Evidence-Based Supplement Protocol
Compounds that compensate for null detox capacity by upregulating remaining GST isoforms or increasing the free glutathione pool.
Induces NRF2 → upregulates remaining GST isoforms (GSTA, GSTP1, NQO1, HMOX1) that are NOT deleted; partially compensates null loss
Non-negotiable for any null genotype — this is the primary compensatory mechanism
Direct substrate replenishment. Null carriers cannot conjugate toxins efficiently — higher free GSH pool creates partial mass-action compensation
Essential alongside sulforaphane; oral absorption is superior in liposomal form
Rate-limiting precursor to glutathione synthesis (γ-GCS step). Increases GSH pool size to compensate for impaired conjugation capacity
Stack with liposomal GSH for comprehensive support; especially important for double-null carriers
Second rate-limiting precursor for GSH (glycine + cysteine + glutamate). Often deficient in high-toxin-load environments
Inexpensive, often overlooked. Critical for completeness of the GSH precursor stack
Hepatoprotective; upregulates GSTA2 and GSTP1 isoforms that remain functional in null carriers; also NRF2 activator
Particularly important for GSTM1 null carriers with alcohol or medication exposure
Required cofactor for glutathione peroxidase (GPx1/4) — the backup pathway when GST conjugation is impaired. Null carriers depend more heavily on GPx
Critical backup pathway support; get selenium from food (Brazil nuts) or supplementation, not both
Regenerates oxidized glutathione (GSSG → GSH) via ascorbate pathway; preserves existing GSH pool in null carriers who deplete faster
Good stack addition; especially relevant for heavy oxidative stress exposure
Universal antioxidant; regenerates GSH, vitamin C, and vitamin E simultaneously; mild NRF2 activator via KEAP1 cysteine modification
Strong general support; use R-ALA form (more bioavailable than racemic mix)
What Null Carriers Should Minimize
These aren't absolute prohibitions — they're exposure categories where null carriers face meaningfully higher risk than the general population.
GSTM1 is the primary enzyme for benzene detoxification. Null carriers have 2–4× higher DNA damage after solvent exposure. Ventilation and protective equipment are non-negotiable.
Heterocyclic amines (HCAs) from charred meat are metabolized partly by GSTM1/GSTT1. Null carriers accumulate more carcinogenic intermediates. Avoid well-done/charred protein.
GSTT1 conjugates some acetaminophen reactive metabolites. Null carriers have less capacity to neutralize hepatotoxic intermediates — especially under oxidative stress.
Taking only vitamin C or E without supporting the GSH pool creates imbalanced redox — antioxidants recycle back to pro-oxidant forms if GSH is depleted in null carriers.
Both GSTM1 and GSTT1 neutralize tobacco carcinogens. Double-null carriers have 2–3× elevated lung cancer risk from smoking compared to positive carriers. Evidence is robust across 40+ studies.
Gene Interaction Map
How your GSTM1/GSTT1 status interacts with other variants in your genome.
NRF2 is the upstream inducer of the remaining functional GST isoforms. If NRF2 is also impaired, the compensatory upregulation pathway fails. NRF2 TT + GSTM1/GSTT1 null = near-complete loss of inducible detox response.
Sulforaphane dose escalation to 60–80mg/day; consider adding EGCG + quercetin to multi-path NRF2 activation
GSTP1 is the third major GST isoform. When GSTM1 null + GSTT1 null + GSTP1 Val/Val co-occur, all three major GST branches are simultaneously impaired. This triple compound is the most severe detox deficit in the Gnosis platform.
Maximum detox support stack: sulforaphane 60mg + liposomal GSH 1g + NAC 1.8g + glycine 5g + selenium 200mcg daily
Fast CBS increases flux through the transsulfuration pathway, producing more cysteine → more GSH raw material. TT CBS can partially compensate for null detox capacity by increasing GSH pool size. This is a rare protective interaction.
If GSTM1 null + CBS TT compound: lean into CBS-supporting nutrients (taurine, molybdenum) AND sulforaphane. The CBS speed is actually protective here.
High TNF-α creates systemic oxidative stress that depletes GSH faster. Null carriers with high TNF-α chronically exhaust their already-limited GSH reserves, creating persistent vulnerability.
Add omega-3 (3g EPA+DHA), curcumin (1g/day), resveratrol. Priority: reduce inflammatory GSH consumption
CYP1B1 metabolizes polycyclic aromatic hydrocarbons and estrogens into reactive quinones. GSTM1/GSTT1 are the primary enzymes that neutralize these quinones. High CYP1B1 + null detox = maximum carcinogenic intermediate accumulation.
Cruciferous vegetables daily (sulforaphane + I3C combination). Minimize PAH exposure. Consider DIM 200mg/day for estrogen quinone management.
TP53 Pro72Arg reduces apoptotic response to DNA damage. When GSTM1/GSTT1 null allows more DNA-damaging compounds to persist, AND TP53 is less responsive to the damage — cell survival after DNA damage increases. This is a theorized compound for certain cancers.
Maximize chemoprevention stack. Regular screening. Sulforaphane activates TP53-independent apoptosis pathways.
When GSTM1 null + GSTT1 null + GSTP1 Val/Val co-occur, all three major GST isoform classes are simultaneously impaired: mu class (zero), theta class (zero), and pi class (reduced 3–6×). The only remaining GST activity comes from alpha class (GSTA1/2) and sigma class (GSTS) — which have narrower substrate profiles.
This compound is uncommon (all three variants independent → ~5–10% of population) but represents an extreme detoxification bottleneck. The clinical implication is not panic — it's precision. These individuals respond most dramatically to the full support stack and benefit most from environmental exposure reduction.
- · Sulforaphane 60–80mg/day (maximum NRF2 induction of remaining isoforms)
- · Liposomal glutathione 1000mg/day
- · NAC 1800mg/day (divided dosing)
- · Glycine 5g/day
- · Selenium (selenomethionine) 200mcg/day
- · Milk thistle 300mg silymarin/day
- · Strict avoidance: smoking, benzene, charred meat, chlorinated solvent exposure
Cancer Risk in Context
The association between GSTM1/GSTT1 null and cancer risk is one of the most extensively studied in pharmacogenomics — with 40+ meta-analyses published since 1994. The key nuances:
GSTM1 null in a non-smoker who eats primarily plant-based foods and avoids solvents has minimal measurable cancer risk elevation. The elevated risk requires the substrate — the carcinogens these enzymes would normally neutralize. Zero exposure → near-zero compound risk. This is why lifestyle modifications are the highest-leverage intervention.
The Fahey/Talalay Johns Hopkins research on sulforaphane and GST null genotypes is among the strongest clinical nutrition evidence available. Null carriers specifically show greater chemoprevention response to broccoli sprout intervention than positive carriers — their NRF2 system is intact and over-compensates when properly activated. This is a case where the genotype predicts intervention response as much as it predicts risk.
Tracking Your Detox Capacity
These biomarkers help monitor intervention effectiveness in null carriers:
Direct measure of your GSH pool. Null carriers who optimize are sometimes measurably higher than positive-carrier non-supplementers.
Urinary DNA oxidation marker. Elevated in null carriers under carcinogen exposure. Sulforaphane intervention significantly reduces 8-OHdG in clinical trials specifically in null carriers.
GPx is the backup pathway when GST is absent. Optimizing selenium (GPx cofactor) and tracking GPx activity monitors compensatory pathway function.
Confirms sulforaphane is being absorbed and metabolized. Some null carriers have altered ITC kinetics. Useful to verify intervention delivery.
GSTM1 null increases hepatic vulnerability to medication and alcohol. Tracking liver enzymes is particularly relevant for null carriers on chronic medications.
Primary Literature
Is Your GSTM1 or GSTT1 Present or Null?
Upload your 23andMe or AncestryDNA raw data to discover your exact null genotype status — and get a personalized protocol based on your full genotype combination, including compound interactions.
Analyze My Genome →